Table 2.
Presence of each radiologic criteria using the definitions created for the model to predict suboptimal cytoreduction (RD >1 cm)
| Characteristic | Criteria present in Mayo validation cohort (N=276) | Criteria present in published model development cohort* (N=350) |
|---|---|---|
| Subcapsular liver lesion or perihepatic lesion >1 cm | 113 (40.9%) | 121 (34.6%) |
| Liver intraparenchymal lesion >1 cm | 12 (4.3%) | 9 (2.6%) |
| Retroperitoneal lymph nodes above the renal hilum (including supradiaphragmatic) >1 cm | 59 (21.4%) | 72 (20.6%) |
| Gastrohepatic ligament/porta hepatis lesion >1 cm | 54 (19.6%) | 73 (20.9%) |
| Gallbladder fossa lesion >1 cm | 41 (14.9%) | 25 (7.1%) |
| Liver intersegmental fissure lesion >1 cm | 21 (7.6%) | 48 (13.7%) |
| Lesser sac lesion >1 cm | 30 (10.9%) | 35 (10.0%) |
| Spleen intraparenchymal lesion >1 cm | 3 (1.1%) | 7 (2.0%) |
| Perisplenic lesion >1 cm | 55 (19.9%) | 59 (16.9%) |
| Root of the SMA lesion >1 cm | 6 (2.2%) | 8 (2.3%) |
| Small bowel mesentery lesion >1 cm | 58 (21.0%) | 61 (17.4%) |
| Omental lesion >1 cm | 221 (80.1%) | 212 (60.6%) |
| Ascites (moderate-severe) | 97 (35.1%) | 154 (44.0%) |
| Diffuse small bowel adhesions/thickening | 53 (19.2%) | 24 (6.9%) |
| Presacral extraperitoneal disease >1 cm | 7 (2.5%) | 4 (1.1%) |
| Tumor invading anterior abdominal wall >1 cm | 13 (4.7%) | 11 (3.1%) |
| Pulmonary metastasis (lung bases) | 3 (1.1%) | 13 (3.7%) |
| Pleural metastasis (lung bases) | 9 (3.3%) | 17 (4.9%) |
*
Data from Suidan 2014 publication
Abbreviations: RD, residual disease; SMA, superior mesenteric artery